Effects of L-ornithine-L-aspartate on the manifestation of minimal hepatic encephalopathy in the dynamics of cytostatic therapy
Journal Title: Сучасна гастроентерологія - Year 2018, Vol 0, Issue 6
Abstract
Objective — to investigate effects of the L-ornithine-L-aspartate (LOLA, Hepa-Merz®) on the clinical manifestations of minimal hepatic encephalopathy (HE) in patients with multiple myeloma (MM) in the dynamics of cytostatic treatment (CT). Materials and methods. The study involved 42 patients with MM who never received CT, from them 18 (42.8 %) men and 24 (57.2 %) women, aged 62.3 ± 8.67 years. Depending on the LOLA (Hepa-Merz®) administration, patients were divided into two groups: group I (n = 20) included patients with MM treated with CT; group II (n = 22) consisted of patients with MM, who additionally were treated with LOLA (Hepa-Merz®) at a daily dose 15 g orally throughout the observation period. The assessment of the patients’ condition was carried out twice: before the treatment and on the 56th day. The parameters of complete blood count, biochemical panel were analyzed; the number connection test was performed. Results. At baseline, in 28 (66.7 %) patients with MM minimal HE was present, which was accompanied by changes in the biochemical panel that correspond to the MM active phase. After two CT courses with no additional LOLA (Hepa-Merz®), the serum creatinine level decreased in 1.8 times (p < 0.05), the HE manifestations reduced according to number connection test results. However, the gamma-glutamyltransferase activity increased in 2.3 times more than normal (p < 0.05). In patients of group II who received the combination of CT and LOLA (Hepa-Merz®), the serum creatinine decreased in 1.8 times compared to the baseline level (p < 0.05), accompanied by HE frequency and degree reduction without functional liver tests violations. Conclusions. Administration of LOLA (Hepa-Merz®) is recommended for patients with MM during CT, it effectively eliminates the manifestations of minimal HE and shows a protective effect on the hepatocytes.
Authors and Affiliations
I. M. Skrypnyk, G. S. Maslova, R. I. Skrypnyk
Keywords
Related Articles
- EP ID EP453993
- DOI 10.30978/MG-2018-6-29
- Views 135
- Downloads 0
A place of plasma substitutes in the treatment of patients with chronic viral hepatitis
Objective — to assess the efficacy of plasma substitute (Reosorbilact) in patients with chronic viral hepatitis. Materials and methods. The investigation involved 60 patients with chronic viral hepatitis (CVH), who were...
The mechanisms of development of irritable bowel syndrome and treatment of abdominal pain in the light of Rome IV criteria
Objective — to assess the clinical efficacy of Capsumen in patients with irritable bowel syndrome (IBS) with pain syndrome. Materials and methods. The investigation involved 17 patients (7 women and 10 men aged 19 to 52...
Mechanisms of formation of the gastroesophageal reflux disease and coronary heart disease comorbidity
Objective — to identify possible transnosological mechanisms for the formation of comorbidity of gastroesophageal reflux disease (GERD) and coronary heart disease (CHD). Materials and methods. The study involved patients...
Leukemoid reactions in the gastroenterologist’s practice
Leukemic reactions (LR) are abnormal blood reactions similar to leukemic (subleukemic), but they are different in their pathogenesis; LRs never transform into leukemia. The article presents several clinical cases, the co...
The issues of concern in the modern pharmacotherapy the gastroesophageal reflux disease: the role and place of prokinetics
The article presents review of modern concepts of the pathophysiological mechanisms of gastroesophageal reflux disease (GERD) development. The issues of the increasing resistance to proton pump inhibitors (PPI) in the co...